Mullish BH. Improving efficacy without increasing side effects? Exploring the impact of a novel GLP-1-glucagon dual receptor agonist upon metabolic dysfunction-associated steatohepatitis. Gastroenterology 2026 Jan 29:S0016-5085(26)00083.
PMID: 41620034